|
Abstract:
Breast Cancer is the most common non-skin malignancy in American women and is the second cause of cancer deaths in this population. Therefore, the need for new therapies is critical. These studies evaluated the therapeutic potential of a novel agent, the protein kinase C modulator, Bryostatin 1 in combination with the taxene, paclitaxel in breast cancer models, in vitro. The studies were designed to evaluate multiple treatment schedules of both agents to determine synergistic combinations. The combination of bryostatin 1 and paclitaxel was studied in four breast cancer cell lines utilizing multiple treatment schedules and no synergistic combination was identified. Several other chemotherapeutic agents (doxorubicin, cisplatin, 5-fluorouracil, & vinorelbine) were also tested in combination with bryostatin 1 using two breast cancer cell lines and three treatment schedules. Again, no synergistic combinations were identified. No synergistic combinations of bryostatin 1 and paclitaxel (as well as the other drugs tested) were identified even though several breast cancer cell lines and multiple treatment schedules were evaluated. These studies suggest that bryostatin 1 in combination with paclitaxel and the other drugs evaluated may not be a promising combination for the treatment of breast cancer.
| Limitations: |
 APPROVED FOR PUBLIC RELEASE |
| Description: |
Annual rept. 1 Jan-31 Dec 1998 |
| Pages: |
13 |
| Report Date: |
JAN 1999 |
| Contract Number: |
DAMD17-97-1-7338 |
| Report Number: |
A321873 |
|
|
|
|
Keywords relating to this report:
